drugset / Trial / NCT04410354

Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19

NCT04410354

Phase 2 Terminated 44 enrolled ViralClear Pharmaceuticals, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to assess the safety and efficacy of merimepodib (MMPD) oral solution when administered in combination with remdesivir in adult patients with advanced COVID-19.

Timeline

Start
2020-06-16
Primary completion
2020-12-01
Completion
2020-12-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Merimepodib Small molecule 400 mg Oral
Comparator Remdesivir Small molecule 100 mg Intravenous

Indications